NASDAQ · CRSP
Healthcare · Biotechnology
$42.62
Down-$3.13 (-6.84%)
Updated Nov 13, 2026, 12:28 PM
SID Score
3.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CRSP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
CRSP closed at $42.62 after 21 trading sessions, down 17.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $45.09 | $45.09 | $42.38 | $42.62 | 2.49M |
| Nov 11, 2026 | $45.97 | $46.31 | $44.49 | $45.75 | 2.68M |
| Nov 10, 2026 | $49.02 | $49.29 | $44.99 | $45.15 | 4.01M |
| Nov 9, 2026 | $50.57 | $51.52 | $48.69 | $50.04 | 1.06M |
| Nov 6, 2026 | $48.98 | $50.27 | $48.41 | $50.07 | 1.24M |
| Nov 5, 2026 | $51.01 | $51.21 | $47.76 | $48.56 | 2.15M |
| Nov 4, 2026 | $51.48 | $52.50 | $50.19 | $51.775 | 1.39M |
| Nov 3, 2026 | $50.26 | $51.86 | $49.62 | $49.99 | 1.29M |
| Nov 2, 2026 | $51.90 | $52.1216 | $49.7001 | $49.99 | 1.03M |
| Oct 30, 2026 | $53.27 | $54.10 | $50.60 | $51.42 | 1.17M |
| Oct 29, 2026 | $54.11 | $55.82 | $53.30 | $54.26 | 1.31M |
| Oct 28, 2026 | $50.48 | $54.17 | $50.10 | $54.11 | 1.13M |
| Oct 27, 2026 | $49.14 | $51.55 | $48.75 | $51.47 | 1.17M |
| Oct 26, 2026 | $49.35 | $50.11 | $48.65 | $49.01 | 1.07M |
| Oct 23, 2026 | $49.31 | $49.68 | $48.02 | $49.39 | 1.93M |
| Oct 22, 2026 | $50.14 | $51.05 | $49.36 | $49.99 | 906.11K |
| Oct 21, 2026 | $50.13 | $50.94 | $49.5538 | $50.50 | 1.17M |
| Oct 20, 2026 | $48.87 | $50.3299 | $47.36 | $49.88 | 2.16M |
| Oct 19, 2026 | $49.83 | $50.30 | $49.09 | $50.04 | 1.18M |
| Oct 16, 2026 | $51.20 | $51.36 | $49.045 | $49.25 | 1.52M |
| Oct 15, 2026 | $50.00 | $52.3725 | $49.76 | $51.52 | 1.35M |
The latest Smart Investors Daily articles mentioning CRSP.
Company
Market Activity
Research & News
CRSP research
Company profile and research snapshot.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 4, 2026 | Wells Fargo | Equal-Weight | — |
| Nov 4, 2026 | Citigroup | Buy | — |
| Nov 3, 2026 | Needham | Buy | — |
| Oct 15, 2026 | UBS | Neutral | — |
| Aug 31, 2026 | Citizens | Market Outperform | — |
No generated briefing is available yet.
Yahoo · Nov 6, 2026
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
SeekingAlpha · Nov 6, 2026
Benzinga · Nov 4, 2026
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.
Yahoo · Nov 4, 2026
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposi
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CRSP.
